Feature | Published:

Bringing up baby

Nature Biotechnology volume 36, pages 393401 (2018) | Download Citation

  • An Erratum to this article was published on 06 August 2018

This article has been updated

More investors are building companies from scratch, with more money than any time in biotech's history.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Change history

  • 26 June 2018

    In the version of this article initially published, on p. 395, right-hand column, Celgene was said to have bought Delinia four months after founding, rather than four months after series A. The error has been corrected in the HTML and PDF versions of the article.

  • 18 July 2018

    In the version of this article initially published, on p. 395, right-hand column, Plan les Ouates was mislocated in France; it is in Switzerland. The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

  1. Brady Huggett is Business Editor at Nature Biotechnology.

    • Brady Huggett

Authors

  1. Search for Brady Huggett in:

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Figures

    Supplementary Figures 1, 2 and Supplementary Tables 1, 2

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4135

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing